SuggestSoft.com

Weonlydo

wodSmtp 1.3.3

wodSmtp 1.3.3: wodSmtp activex client component used to deliver e-mail messages to server Activex client component used to deliver e-mail messages directly to the server of the recipient, using SMTP protocol. It automatically finds appropriate server where message should be delivered, or uses SmartHost through Hostaname property. It includes several one-line methods for sending entire email (including attachments).



wodCrypt 1.3.2: wodCrypt is a component that provides strong encryption for your applications
wodCrypt 1.3.2

Lightweight component that provides strong encryption for your applications. It provides supports for most common crypto algorithms, such as AES, DES, TripleDES, Blowfish, Cast, RC2, RC4, RC5 for symmetric encryption and decryption, RSA, DSA, for making and verifying signatures, and MD5, SHA1 for creating hashes

crypt, component, security, weonlydo, encryption, activex



wodBeep 1.0.0.0: ActiveX component is a peer-to-peer connection
wodBeep 1.0.0.0

ActiveX component is a peer-to-peer connection convenient to label each peer to behave in context of Listener(Server) or Initiator(Client). Component comes with several profiles included such as: SINK/ECHO profiles for testing, ROT13 profile that will grab message data, ZIP Tuning profile that will compress contents of messages on the fly, SYSLOG Raw and Cooked profiles for transmitting(and recieving) syslog messages...

protocol, wodbeep, connection, asynchronus, secure, beep, weonlydo, security, peer, communicate



More Results: 1  2  

World IT News

  • PC Mall Chooses iZ3D 22-Inch Widescreen 3D MonitorsPopular 3D Monitor Now Features New Drivers for 64 Bit Compatibility, CrossFireX and Open GL Quad Buffer Support
  • New IBM Consulting Offerings Help Clients Be Greener, More EthicalImproving Corporate Social Responsibility Can Grow Revenue, Market Share
  • Are Your Computers Sky Divers?BURBANK, CA--(Marketwire - June 30, 2008) - Astute risk management defines success in theinsurance industry. Premiums charged to the company's customers reflectthat relation of risk to profit, while the riskiest ventures are avoidedentirely. Translating risk to the IT world would likely bring securitysoftware solutions to mind. Not managing those risks can result in dataloss, corporate espionage, and other nasty events. It may come as a surprise that file fragmentation can be risky businesstoo. Fragmentation creates many more unattractive side effects than a slowcomputer. The insurance policyholder who smokes is a higher risk than theone who does not, and subsequently they pay a higher premium.
  • Labwire Completes First Conversion of USIS BusinessHOUSTON, TX--(Marketwire - June 30, 2008) - Labwire, Inc. ( PINKSHEETS : LBWR ), a leadingprovider of employee screening solutions and canine security andsurveillance services, announced today that it has completed the firstconversion of business under the USIS agreement. "This is a very important accomplishment for us," commented Mr. DexterMorris, Chairman and Chief Executive Officer of Labwire. "Our team workedwell with USIS personnel, and the conversion was completed smoothly and onschedule. We are already planning the next interfaces and data transfersand exploring additional business possibilities with USIS. I am veryexcited about the potential of this strategic relationship."
  • FDAAdvisoryCommittee.com to Webcast the FDA Endocrinologic and Metabolic Drugs Advisory Committee Hearing on July 1st & 2nd in Conjunction With TalkPointNEW YORK, NY--(Marketwire - June 30, 2008) - TalkPoint , leading provider of theTools, Technology and Services for Interactive Internet Broadcasting, and FDAAdvisoryCommittee.com , the leadingwebcast and DVD source for FDA Advisory Committee Meetings, today announcedthat TalkPoint will be powering the Endocrinologic and Metabolic DrugsAdvisory Committee Meeting scheduled for July 1st & 2nd. The July Endocrinologic and Metabolic Drugs Advisory Committee Meeting isbeing held to further discuss whether to insist that new diabetes drugshave a positive impact on cardiovascular disease and life span. At issue iswhat benchmarks the FDA should use to approve diabetes drugs. The two-daymeeting of FDA officials and outside medical experts, set to start Tuesday,will discuss whether the agency should require additional, more rigorousbenchmarks, such as proof a drug ultimately lowers risks for cardiovasc